{"id":"https://openalex.org/W2954313239","doi":"https://doi.org/10.1158/1538-7445.am2019-4121","title":"Abstract 4121: Preclinical characterization of CS1003, a novel clinical-stage PD-1 monoclonal antibody","display_name":"Abstract 4121: Preclinical characterization of CS1003, a novel clinical-stage PD-1 monoclonal antibody","publication_year":2019,"publication_date":"2019-07-01","ids":{"openalex":"https://openalex.org/W2954313239","doi":"https://doi.org/10.1158/1538-7445.am2019-4121","mag":"2954313239"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2019-4121","doi":"https://doi.org/10.1158/1538-7445.am2019-4121","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-4121","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045272859","display_name":"Li Fu","orcid":"https://orcid.org/0000-0001-7761-5618","observed_orcids":["https://orcid.org/0000-0001-7761-5618","https://orcid.org/0009-0006-4275-3264"]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Fu Li","raw_affiliation_strings":["1CStone Pharmaceuticals Co., Ltd., Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1CStone Pharmaceuticals Co., Ltd., Shanghai, China;","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103226158","display_name":"Jingrong Li","orcid":"https://orcid.org/0000-0002-3945-6713","observed_orcids":["https://orcid.org/0000-0002-3945-6713","https://orcid.org/0009-0003-2813-9389"]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jingrong Li","raw_affiliation_strings":["1CStone Pharmaceuticals Co., Ltd., Shanghai, China;","2Wuxi Biologics Co. Ltd., Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1CStone Pharmaceuticals Co., Ltd., Shanghai, China;","institution_ids":["https://openalex.org/I4405267831"]},{"raw_affiliation_string":"2Wuxi Biologics Co. Ltd., Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022619356","display_name":"Ke Yin","orcid":"https://orcid.org/0000-0002-8196-1377","observed_orcids":["https://orcid.org/0000-0002-8196-1377"]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Ke Yin","raw_affiliation_strings":["1CStone Pharmaceuticals Co., Ltd., Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1CStone Pharmaceuticals Co., Ltd., Shanghai, China;","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100390052","display_name":"Juan Zhang","orcid":"https://orcid.org/0000-0003-1780-8340","observed_orcids":["https://orcid.org/0000-0003-1780-8340"]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Juan Zhang","raw_affiliation_strings":["1CStone Pharmaceuticals Co., Ltd., Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1CStone Pharmaceuticals Co., Ltd., Shanghai, China;","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003885252","display_name":"Zhenhu Li","orcid":"https://orcid.org/0000-0001-8574-783X","observed_orcids":["https://orcid.org/0000-0001-8574-783X"]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Zhenhu Li","raw_affiliation_strings":["1CStone Pharmaceuticals Co., Ltd., Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1CStone Pharmaceuticals Co., Ltd., Shanghai, China;","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005067701","display_name":"Liang Lu","orcid":"https://orcid.org/0009-0005-8851-2514","observed_orcids":["https://orcid.org/0009-0005-8851-2514"]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Liang Lu","raw_affiliation_strings":["1CStone Pharmaceuticals Co., Ltd., Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1CStone Pharmaceuticals Co., Ltd., Shanghai, China;","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003869570","display_name":"Yuanwu Bao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yuanwu Bao","raw_affiliation_strings":["1CStone Pharmaceuticals Co., Ltd., Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1CStone Pharmaceuticals Co., Ltd., Shanghai, China;","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101498648","display_name":"Dan Pu","orcid":"https://orcid.org/0000-0001-6628-9714","observed_orcids":["https://orcid.org/0000-0001-6628-9714"]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Dan Pu","raw_affiliation_strings":["1CStone Pharmaceuticals Co., Ltd., Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1CStone Pharmaceuticals Co., Ltd., Shanghai, China;","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101708266","display_name":"Zhen Qin","orcid":"https://orcid.org/0000-0002-1835-1453","observed_orcids":["https://orcid.org/0000-0002-1835-1453","https://orcid.org/0009-0000-4059-5940"]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Zhen Qin","raw_affiliation_strings":["1CStone Pharmaceuticals Co., Ltd., Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1CStone Pharmaceuticals Co., Ltd., Shanghai, China;","institution_ids":["https://openalex.org/I4405267831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111671086","display_name":"Yong Tang Zheng","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yong Zheng","raw_affiliation_strings":["2Wuxi Biologics Co. Ltd., Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Wuxi Biologics Co. Ltd., Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050027442","display_name":"Baotian Yang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Baotian Yang","raw_affiliation_strings":["2Wuxi Biologics Co. Ltd., Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Wuxi Biologics Co. Ltd., Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jing Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jing Li","raw_affiliation_strings":["1CStone Pharmaceuticals Co., Ltd., Shanghai, China;","2Wuxi Biologics Co. Ltd., Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1CStone Pharmaceuticals Co., Ltd., Shanghai, China;","institution_ids":["https://openalex.org/I4405267831"]},{"raw_affiliation_string":"2Wuxi Biologics Co. Ltd., Shanghai, China","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001038313","display_name":"Xinzhong Jon Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267831","display_name":"CStone Pharmaceuticals (China)","ror":"https://ror.org/04m2ekz50","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267831"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xinzhong Jon Wang","raw_affiliation_strings":["1CStone Pharmaceuticals Co., Ltd., Shanghai, China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1CStone Pharmaceuticals Co., Ltd., Shanghai, China;","institution_ids":["https://openalex.org/I4405267831"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"79","issue":"13_Supplement","first_page":"4121","last_page":"4121"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-pd-1-monoclonal-antibody","display_name":"anti-PD-1 monoclonal antibody","score":0.9819999933242798},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.8500000238418579},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.7879999876022339},{"id":"https://openalex.org/keywords/pd-l2","display_name":"PD-L2","score":0.9959999918937683},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.7839999794960022},{"id":"https://openalex.org/keywords/humanized-antibody","display_name":"humanized monoclonal antibody","score":0.6359999775886536},{"id":"https://openalex.org/keywords/cross-reactivity","display_name":"cross-reactivity","score":0.6299999952316284},{"id":"https://openalex.org/keywords/t-cell-activation","display_name":"T cell activation","score":0.5569999814033508},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8820000290870667},{"id":"https://openalex.org/keywords/mc38-colon-carcinoma","display_name":"MC38 colon carcinoma","score":0.7559999823570251},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8629999756813049},{"id":"https://openalex.org/keywords/repeated-dose-toxicity","display_name":"repeated-dose toxicity","score":0.781000018119812}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.7020716667175293},{"id":"https://openalex.org/C195616568","wikidata":"https://www.wikidata.org/wiki/Q128711","display_name":"Epitope","level":3,"score":0.6759292483329773},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.6379615068435669},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5849494934082031},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5520192384719849},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.5444108843803406},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.5069063305854797},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5025606155395508},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.4627653956413269},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.458257794380188},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.4468576908111572},{"id":"https://openalex.org/C2777092746","wikidata":"https://www.wikidata.org/wiki/Q5939625","display_name":"Humanized antibody","level":4,"score":0.4202394187450409},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.41017797589302063},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.40073198080062866},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3749428987503052},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.37063705921173096},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.35375016927719116},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3461565673351288}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2019-4121","doi":"https://doi.org/10.1158/1538-7445.am2019-4121","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-4121","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3029868931","https://openalex.org/W3081548758","https://openalex.org/W2740703372","https://openalex.org/W2885709677","https://openalex.org/W4402131488","https://openalex.org/W2898134648","https://openalex.org/W2599048038","https://openalex.org/W2399033183","https://openalex.org/W2099609050","https://openalex.org/W2236929991"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"The":[2,310],"programmed":[3],"cell":[4,150,170],"death":[5],"protein":[6,13],"1":[7],"receptor":[8],"(PD-1)":[9],"is":[10,57,295,315,347],"an":[11],"immune-checkpoint":[12],"that":[14],"negatively":[15],"regulates":[16],"the":[17,40,48,69,241,261,284,352,408],"immune":[18,35],"system":[19],"to":[20,24,33,67,74,175,178,350],"avoid":[21,34],"collateral":[22],"damage":[23],"self-tissues.":[25],"Tumors":[26],"hijack":[27],"this":[28],"mechanism":[29],"as":[30,80,118,130,132,195,197],"a":[31,58,63,111,221,249,279,296,398],"way":[32],"detection":[36],"and":[37,141,152,167,173,260,304,321,356],"destruction.":[38],"Presently,":[39],"FDA":[41],"has":[42],"approved":[43],"three":[44],"anti-PD-1":[45,60,298],"antibodies":[46],"for":[47,122,332,345,411],"treatment":[49],"in":[50,84,162,192,198,207,215,225,257,267,307,335,359],"more":[51],"than":[52],"ten":[53],"cancer":[54],"types.":[55],"CS1003":[56,136,147,187,202,253,277,294,314,346],"novel":[59,297,399],"mAb":[61,299],"recognizing":[62],"unique":[64,311],"epitope":[65],"developed":[66],"disrupt":[68],"PD-1":[70,94,143,157,165,401],"interaction":[71],"with":[72,86,104,144,159,181,210,240,273,283,300,318,361],"PD-L1/PD-L2":[73],"restore":[75],"or":[76,83,183],"improve":[77],"T-cell":[78],"function":[79],"stand-alone":[81],"therapy":[82,334],"combination":[85,333],"other":[87],"approaches.":[88],"Methods:":[89],"A":[90,341],"panel":[91],"of":[92,164,217,290,313,396,407],"rat":[93],"mAbs":[95,103],"were":[96,107,238],"generated":[97],"through":[98],"conventional":[99,193],"hybridoma":[100],"technology.":[101],"Several":[102],"favorable":[105,280,301],"characteristics":[106,303],"further":[108,123,328],"humanized.":[109],"CS1003,":[110,397],"humanized,":[112],"hinge-stabilized":[113],"IgG4":[114],"mAb,":[115],"was":[116,254,264,271],"selected":[117],"our":[119],"lead":[120],"candidate":[121],"characterization":[124,395],"including":[125],"antigen":[126],"binding,":[127],"biophysical":[128],"properties":[129,237],"well":[131,196,255],"functional":[133],"characterization.":[134],"Results:":[135],"binds":[137],"mouse,":[138],"cynomolgus":[139,226,258,308],"monkey":[140],"human":[142,208,320],"similar":[145],"affinity.":[146],"bound":[148],"PD-1-expressing":[149],"lines":[151],"chronically-activated":[153],"T":[154,169],"cells,":[155],"blocked":[156],"interactions":[158],"PD-L1/PD-L2,":[160],"resulting":[161],"inhibition":[163],"signaling,":[166],"enhanced":[168],"cytokine":[171],"secretion":[172],"proliferation":[174],"levels":[176],"comparable":[177],"those":[179],"observed":[180,213],"nivolumab":[182],"pembrolizumab":[184],"reference":[185],"molecules.":[186],"showed":[188,203],"significantly":[189],"anti-tumor":[190,357],"activity":[191,358],"MC38":[194],"hPD-1":[199],"knock-in":[200],"mice.":[201],"no":[204],"unexpected":[205],"cross-reactivity":[206,317],"tissues,":[209],"specific":[211],"staining":[212],"primarily":[214],"lymphocytes":[216],"lymphoid":[218],"organs.":[219],"In":[220,248],"pharmacokinetic":[222],"(PK)":[223],"study":[224,344],"monkeys":[227,259],"following":[228],"single":[229],"intravenous":[230],"administration":[231],"at":[232],"multiple":[233,268],"dose":[234,288],"levels,":[235],"PK":[236,355],"linear":[239],"proportionally":[242],"increasing":[243],"exposures":[244],"from":[245],"2-18":[246],"mg/kg.":[247,292],"repeated-dose":[250],"toxicity":[251],"study,":[252],"tolerated":[256],"major":[262],"finding":[263],"mononuclear":[265],"infiltration":[266],"organs,":[269],"which":[270],"consistent":[272],"its":[274,316,330],"pharmacologic":[275],"activity.":[276],"demonstrated":[278],"safety":[281,305],"profile":[282,306],"highest":[285],"non-severely":[286],"toxic":[287],"(HNSTD)":[289],"100":[291],"Conclusion:":[293],"preclinical":[302],"monkeys.":[309],"feature":[312],"both":[319],"murine":[322],"PD-1.":[323],"This":[324],"should":[325],"greatly":[326],"facilitate":[327],"evaluation":[329],"potential":[331],"various":[336],"syngeneic":[337],"mouse":[338],"tumor":[339],"models.":[340],"phase":[342],"I":[343],"being":[348],"conducted":[349],"evaluate":[351],"safety,":[353],"tolerability,":[354],"patients":[360],"advanced":[362],"tumors":[363],"[NCT03475251].":[364],"Citation":[365],"Format:":[366],"Fu":[367],"Li,":[368,370,376,390],"Jingrong":[369],"Ke":[371],"Yin,":[372],"Juan":[373],"Zhang,":[374],"Zhenhu":[375],"Liang":[377],"Lu,":[378],"Yuanwu":[379],"Bao,":[380],"Dan":[381],"Pu,":[382],"Zhen":[383],"Qin,":[384],"Yong":[385],"Zheng,":[386],"Baotian":[387],"Yang,":[388],"Jing":[389],"Xinzhong":[391],"Jon":[392],"Wang.":[393],"Preclinical":[394],"clinical-stage":[400],"monoclonal":[402],"antibody":[403],"[abstract].":[404],"In:":[405],"Proceedings":[406],"American":[409],"Association":[410],"Cancer":[412,426],"Research":[413],"Annual":[414],"Meeting":[415],"2019;":[416],"2019":[417],"Mar":[418],"29-Apr":[419],"3;":[420],"Atlanta,":[421],"GA.":[422],"Philadelphia":[423],"(PA):":[424],"AACR;":[425],"Res":[427],"2019;79(13":[428],"Suppl):Abstract":[429],"nr":[430],"4121.":[431]},"counts_by_year":[],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2019-07-12T00:00:00"}